Fresenius Medical Care Deutschland GmbH
Clinical trials sponsored by Fresenius Medical Care Deutschland GmbH, explained in plain language.
A dialysis care provider, subsidiary of Fresenius Medical Care.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New dialysis salt strategy aims to reduce fluid gain and dizziness Results expected Dec 2026 (estimated)
- New blood filter could improve treatment for autoimmune diseases Results expected Dec 2026 (estimated)
- New dialysis tech aims to improve waste removal for kidney patients Results expected Aug 2027 (estimated)
-
Blood filter shows promise for autoimmune patients
Disease control CompletedThis study looked at a device called GLOBAFFIN that filters antibodies from the blood to help people with autoimmune diseases. It involved 34 adults and measured how much harmful antibodies were removed and if patients felt better. The goal was to see if the device is safe and wo…
Sponsor: Fresenius Medical Care Deutschland GmbH • Aim: Disease control
Last updated Jun 26, 2026 14:18 UTC
-
Can dialysis filters improve kidney recovery? a data review seeks answers
Knowledge-focused CompletedThis study looks back at treatment records from 119 people with kidney failure who underwent haemodialysis using Genius SleddFlux filters, Ultraflux AV 600 S filters, and Genius 90 concentrates. The goal is to assess how well these devices performed in acute and chronic dialysis …
Sponsor: Fresenius Medical Care Deutschland GmbH • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC